The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...

Nanowear, a leader in home-based cardiometabolic digital diagnostics announced that SimpleSense™, a nanotechnology-enabled wearable, mobile and software diagnostics platform, will ingest glucose data ...

The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...

At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system,1 ...

Insulet (Nasdaq:PODD) announced today that it made its Omnipod 5 automated insulin delivery system available in several new ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Insulet Corporation (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its revolutionary Omnipod 5 Automated Insulin ...

Insulet Corporation (NASDAQ:PODD) showcases a strong financial performance with a ROIC of 16.28% and a WACC of 10.24%, ...

Dexcom received a warning letter from the FDA on 4 March, detailing shortcomings in the company’s manufacturing processes and quality management systems found by the FDA during an inspection of ...

Dexcom said the warning letter, which the FDA has yet to publish, describes non-conformities in the manufacturing processes and quality management systems at the two facilities. The company does ...

Dexcom said the warning letter, which the FDA has yet to publish, describes non-conformities in the manufacturing processes and quality management systems at the two facilities. The company does not ...